PReS-FINAL-2061: Abatacept in therapy of juvenile idiopathic arthritis in real clinical practice

Ítems similars

• Ten years of experience of biologics in juvenile idiopathic arthritis: focus for the reasons of withdrawals
  per: Arsenyeva, Svetlana V, et al.
  Publicat: (2014)
• PReS-FINAL-2076: Single centre experience of biologics in clinical practice of systemic juvenile idiopatic arthritis
  per: Kaleda, MI, et al.
  Publicat: (2013)
• PReS-FINAL-2014: Excellent results of the conventional treatment in a child with late-diagnosed juvenile dermatomyositis with severe calcinosis
  per: Nikishina, IP, et al.
  Publicat: (2013)
• PReS-FINAL-2062: The need for conducting different rehabilitation complexes for patients with juvenile idiopathic arthritis (JIA)
  per: Shelepina, TA, et al.
  Publicat: (2013)
• PReS-FINAL-2138: Abatacept (orencia) in treatment of different types of juvenile idiopathic arthritis
  per: Zholobova, ES, et al.
  Publicat: (2013)